Partially Mismatched Related-Donor Bone Marrow Transplantation for Pediatric Patients With Acute Leukemia: Younger Donors and Absence of Peripheral Blasts Improve Outcome

Autor: Lee C, SH Abhyankar, N. P. Christiansen, Kerry D. Bridges, Adrian P. Gee, Henslee-Downey Pj, Rudolph S. Parrish, S.S. Geier, Pati Ar, Linda J. Hazlett, K. Godder, Karen S. Goon-Johnson, K. Y. Chiang

Publikováno v: Journal of Clinical Oncology. 18:1856-1866

PURPOSE: To extend access to bone marrow transplantation (BMT), we used partially mismatched related donors (PMRD) for pediatric patients with acute leukemia. In this report we sought to determine pretransplantation factors that might predict outcome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed4773d768f4ec77ae5c77fcf6dd917
https://doi.org/10.1200/jco.2000.18.9.1856

Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant

Autor: SH Abhyankar, Adrian P. Gee, Pati Ar, S.S. Geier, Robert G. Best, Henslee-Downey Pj, Lawrence S. Lamb, K. Godder

Publikováno v: Bone Marrow Transplantation. 22:111-113

Graft rejection following bone marrow transplantation is more common in patients who receive their grafts from alternative donors and whose marrow is T cell depleted. Rejection in these patients is mediated by persistent host cells that interfere wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9090113d166b11f4997c43513b54a4d2
https://doi.org/10.1038/sj.bmt.1701278

Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news

Autor: Henslee-Downey Pj, Joyce M, SH Abhyankar, Lawrence S. Lamb, Adrian P. Gee, Maryalice Stetler-Stevenson, Robbins Nf

Publikováno v: Bone marrow transplantation. 19(11)

Allogeneic BMT offers the possibility of cure for a variety of hematopoietic malignancies, but disease relapse remains a major cause of treatment failure. This report describes two cases in which flow cytometric cell sorting (FACS) and molecular chim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37dce112558dc699b15f3e4f8ff0ddde
https://pubmed.ncbi.nlm.nih.gov/9193762

Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review.

Autor: Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; Division of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Florida, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Khan MA; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Sarfraz Z; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Zulfiqar F; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Qasim H; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Bansal R; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Brownback K; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Abhyankar SH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA. Electronic address: mmushtaq@kumc.edu.

Publikováno v: Transplant immunology [Transpl Immunol] 2024 Oct 04; Vol. 87, pp. 102135. Date of Electronic Publication: 2024 Oct 04.

Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation.

Autor: Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Lutfi F; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., DeJarnette S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Al-Ramahi JS; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Li K; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Bansal R; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Abdelhakim H; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Abhyankar SH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA., Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2024 Apr; Vol. 65 (4), pp. 493-502. Date of Electronic Publication: 2024 Jan 02.